Tamsulosin Hydrochloride
Product Images NDC 53002-1663

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Tamsulosin Hydrochloride (NDC 53002-1663). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rpk Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl530021663)

Tamsulosin Hydrochloride 0.4 mg capsules label from RPK Pharmaceuticals, Inc. The label indicates the medication is supplied in a package of 100 capsules, with instructions to take one capsule daily or as directed by a healthcare provider. The label includes space for clinic and prescriber information, dosage instructions, and various barcode and regulatory details.*

FDA Label Image

Figure 1 Mean Plasma Tamsulosin Hydrochloride Concentrations Following Single-dose Administration Of Tamsulosin Hydrochloride Capsules 0.4 mg Under Fasted And Fed Conditions (n=8) (Tamsulosin Fig1)

A line graph showing mean plasma concentrations of Tamsulosin Hydrochloride (ng/mL) over time (hours) following a single 0.4 mg dose of Tamsulosin Hydrochloride capsules. The graph compares concentrations under fasted versus fed conditions over a 36-hour period with distinct curves for each condition.*

FDA Label Image

Figure 2a Mean Change From Baseline In Total Aua Symptom Score (0 To 35) Study 1 (Tamsulosin Fig2)

Line graph titled 'Figure 2A Mean Change from Baseline in Total AUA Symptom Score (0 to 35) Study 1' showing mean change over treatment duration in weeks (0 to 13 and LOCF) for three groups: 0.8 mg dosage, 0.4 mg dosage, and placebo. The y-axis measures mean change from 0 to -11, and the x-axis represents weeks. The 0.8 mg group shows the greatest decrease in symptom score over time, followed by 0.4 mg and placebo groups.*

FDA Label Image

Figure 2b Mean Change From Baseline In Total Aua Symptom Score (0 To 35) Study 2 (Tamsulosin Fig3)

A line graph titled 'Figure 2B Mean Change from Baseline in Total AUA Symptom Score (0 to 35) Study 2,' showing mean change on the vertical axis and duration of treatment in weeks on the horizontal axis. The graph compares mean symptom score changes over 13 weeks among three treatment groups: 0.8 mg dose, 0.4 mg dose, and placebo, with respective symbols (circle, triangle, square). Sample sizes at various time points are noted below the horizontal axis.*

FDA Label Image

Figure 3a Mean Increase In Peak Urine Flow Rate (ml/sec) Study 1 (Tamsulosin Fig4)

A line graph titled 'Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 1' showing mean change in mL/sec on the y-axis and duration of treatment in weeks on the x-axis. It compares treatments of 0.8 mg, 0.4 mg, and placebo over a 13-week period plus last observation carried forward (LOCF), illustrating how peak urine flow rate changes over time for each treatment group.*

FDA Label Image

Figure 3b Mean Increase In Peak Urine Flow Rate (ml/sec) Study 2 (Tamsulosin Fig5)

A line graph titled 'Figure 3B Mean Increase in Peak Urine Flow Rate (mL/Sec) Study 2' showing mean change in mL/sec on the vertical axis versus duration of treatment in weeks on the horizontal axis. It compares three treatments: 0.8 mg, 0.4 mg, and placebo, with data points plotted over 0 to 13 weeks and a last observation carried forward (LOCF) point. The 0.8 mg and 0.4 mg treatments show higher increases in peak urine flow rate compared to placebo over time.*

FDA Label Image

Chemical Structure (Tamsulosin Str)

Chemical structure of Tamsulosin Hydrochloride, showing the molecular arrangement including aromatic rings, functional groups, and the hydrochloride component.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.